NCT05652647 - A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 21, 2022

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions

Healthy Participants

Interventions

DRUG

Oral [14C]PF-07081532

A single oral dose of \[14C\]PF-07081532, will be administered as a liquid formulation in study period 1.

DRUG

Oral PF-07081532 and IV [14C]PF-07081532

In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-07081532 will be administered via intravenous infusion.

Trial Locations (1)

9728 NZ

PRA Health Sciences, Groningen